Intra-Cellular Therapies (NASDAQ: ITCI) has announced positive topline results from its Phase 3 clinical trial into lumateperone for the treatment of bipolar depression, sending its stock price catapulting higher.
“Our program now has confirmatory evidence of efficacy and a favorable safety and tolerability profile of lumateperone in bipolar depression,” commented Dr Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
The study was conducted in five countries, including the USA, with a total of 529 patients.
Sponsored content
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
ITCI stated that lumateperone “met the primary endpoint by demonstrating a statistically significant improvement compared to placebo.”
ITCI share price…
Source: TradingView
The news has resulted in ITCI’s share price climbing over 65% higher to $30.46 per share after closing Tuesday’s trading session at $18.43. Its share price has increased by 54% in the last month.
Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.
